FiercePharma

Ariosa's Harmony™ Prenatal Test shown to be superior to conventional pregnancy screening for Down syndrome (Trisomy 21) in largest clinical trial

New England Journal of Medicine publishes findings of largest non-invasive prenatal testing (NIPT) study involving more than 18,500 expectant mothers "This landmark study supports the use of NIPT as a ...
Business Wire

Affymetrix and Ariosa Diagnostics Announce Signing of Multi-Year Supply Agreement in Support of Ariosa’s Non-Invasive Prenatal Test

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...
FiercePharma

Ariosa grants licenses to laboratories to perform non-invasive prenatal testing (NIPT) based on Harmony™ Prenatal Test technology

SAN JOSE, Calif., June 11, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY). Ariosa Diagnostics, Inc., a global leader in non-invasive prenatal testing (NIPT) technology and maker of the Harmony ...
TASS

Microarray technology proves superior to sequencing for non-invasive prenatal testing

Ariosa Diagnostics announced that its scientists have successfully tested and implemented a microarray DNA quantification method for Ariosa's Harmony Non-Invasive Prenatal Test SAN JOSE, California, ...
TASS

Harmony Prenatal Test to be superior to conventional pregnancy screening for Down syndrome

New England Journal of Medicine publishes findings of largest non-invasive prenatal testing study involving more than 18,500 expectant mothers SAN JOSE, California, April 2 /PRNewswire/ -- Roche (SIX: ...